LeonaBio (LONA) EBITDA (2019 - 2026)

LeonaBio (LONA) has 8 years of EBITDA data on file, last reported at -$17.2 million in Q1 2026.

• On a quarterly basis, EBITDA fell 80.52% year-over-year to -$17.2 million in Q1 2026; TTM through Mar 2026 was -$109.9 million, a 32.86% decrease from a year earlier, with the FY2025 full-year figure at -$102.3 million, down 1.35% from the prior year.
• EBITDA for Q1 2026 stood at -$17.2 million, up from -$78.6 million in the prior quarter.
• Over the last five years, EBITDA for LONA reached as high as -$6.9 million in Q3 2025 and fell as low as -$78.6 million in Q4 2025.
• Historically, EBITDA has averaged -$26.5 million across 5 years, with a median of -$27.7 million in 2024.
• On a YoY basis, EBITDA climbed as much as 76.79% in 2025 and fell as far as 404.72% in 2025.
• Year by year, EBITDA stood at -$32.9 million in 2022, then gained by 11.88% to -$29.0 million in 2023, then soared by 46.35% to -$15.6 million in 2024, then tumbled by 404.72% to -$78.6 million in 2025, then soared by 78.09% to -$17.2 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$17.2 million in Q1 2026, -$78.6 million in Q4 2025, and -$6.9 million in Q3 2025.